A new, post-hoc study has reported that adalimumab, used as monotherapy, led to positive clinical, functional, and radiographic outcomes in patients with rheumatoid arthritis (RA) for up to 3 years in more than half of patients who reached low disease activity (LDA) following combination therapy.
Adalimumab, used as monotherapy, led to positive clinical, functional, and radiographic outcomes in patients with rheumatoid arthritis (RA) for up to 3 years in more than half of patients who reached low disease activity (LDA) following combination therapy, according to a new, posthoc study.
The researchers drew from the open-label extension of the phase 3 PREMIER study, in which patients with RA were randomized to receive adalimumab monotherapy, methotrexate monotherapy, or combination therapy with methotrexate and adalimumab, reported The Center for Biosimilars®. All patients who completed the 2-year study were eligible for the open-label extension, in which they received adalimumab at 40 mg every other week for up to 8 years, with the option to add methotrexate if deemed necessary by the investigator. In total, 183 patients enrolled in the open-label extension, and 140 of them (77%) were in an LDA state at year 2.
According to the current, posthoc study, 84 patients (60%) used adalimumab alone, while 56 (40%) reinitiated methotrexate in combination with adalimumab during the extension period. A total of 60 patients in monotherapy and 44 patients in combination therapy completed 3 years of treatment. Patients 65 or older were more likely to add methotrexate, and those who reinitiated methotrexate generally had higher measures of disease activity than those who remained on adalimumab monotherapy.
Read the full article on The Center for Biosimilars®.
Reference
Keystone EC, Breedveld FC, Kupper H, Li Y, Florentius S, Sainsbury I. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. RMD Open. 2018;4:e000637. doi: 10.1136/rmdopen-2017-000637.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More